Tandem Diabetes Care

Tandem Diabetes Care

Develops subcutaneous insulin pumps and software

Quality Data Analyst Intern

Summer 2026Posted on 5/16/2026
$30 - $41/hr
Internship
San Diego, CA, USA
Hybrid

Hybrid role; on-site required in San Diego, CA.

No H1B Sponsorship

About the job

Requirements
  • Experienced with MS Office (Word, Excel, Outlook, PowerPoint) and effectively use MiniTab or other applicable statistical software.
  • Possess analytical skills and the ability to work independently.
  • Good organizational skills with the ability to prioritize workload.
  • Able to effectively convey information related to work product in one on one conversation or in a group.
  • Able to work effectively in a team environment.
  • Strong analytical and problem-solving skills. Able to present analysis to various stakeholders.
  • Technical knowledge of database and reporting tools.
  • Experience creating interactive dashboards using tools like Power BI or Tableau.
  • Experience with extracting, transforming, and loading data from various data sources into a single data report.
  • Coding skills in languages such as SQL, Python, or equivalent. Experience with Databricks is a plus.
  • Strong knowledge and application of principles outlined in Good Manufacturing Practices (GMP).
  • Capable of producing, interpreting and analyzing results using statistical methodology, including control charts.
  • Able to assert own ideas and persuade others through effectively consolidating, evaluating, and presenting relevant information.
  • Experience working with large datasets and performing data analysis using statistical methods.
  • Continuously monitor and initiate improvement opportunities with data quality and integrity.
  • Adept at seeing change as an opportunity to improve business performance.
  • Excellent verbal and written communication skills and flexibility to function in a fast paced and innovative environment.
  • Knowledge of data governance and data security best practices.
  • Able to alter behavior and opinions in light of new information.
  • Knowledge of problem solving methodologies: 5 why’s analysis, Cause and Effect diagrams, etc.
Responsibilities
  • Partners with Quality Engineering and cross-functional team members to conduct data analysis reports to support post market risk management activities, product monitoring and quality investigations.
  • Define and implement Power BI dashboards, reports and analyses associated with post market surveillance data and metrics that can make data and insights more easily available to non-technical stakeholders.
  • Works with Business Intelligence and IT team members to develop and implement IT solutions to support the company’s analytics needs.
  • Collaborates with others in Operations, R&D Quality, Customer Technical Support, Clinical Evaluation, Failure Investigation, Risk Management, Global Post Market Surveillance and other internal groups.
  • Quality Data Analyst Interns are also responsible for: Collaborates with stakeholders across Tandem’s business units to provide scalable reporting and analytics solutions associated with post market surveillance data.
  • Creates interactive and automated Power BI dashboards and data reports.
  • Collaborate with data scientists, data engineers, and other IT professionals to deliver comprehensive data solutions and reports to increase data analysis efficiencies.
  • Provides ad-hoc analyses and written reports as needed.
  • Participates in problem definition and user needs gathering with project teams and business process owners.
  • Facilitates and participates on cross-functional process improvement teams to drive operational quality excellence and cost savings initiatives.
  • Trains cross-functional stakeholders on data use and access.
  • Enables non-technical stakeholders to quickly answer key questions and make better and faster decisions through easy access to data and analytics tools.
  • Assists in incorporating data from multiple sources including product, ERP, CRM, and other business applications to present consolidated views of post market surveillance data.
  • Confirms completion of required training plan before assuming job responsibilities.
  • Ensures compliance with company policies, including Privacy/HIPAA, and other legal and regulatory requirements.
  • Other responsibilities as assigned.
  • Performs other duties as assigned.
  • Minimum experience items relocated into responsibilities:
  • Assists in collecting, cleaning and validating data from multiple sources
  • Support the development and maintenance of dashboards, reports, and visualizations
  • Perform basic data analysis to identify trends, patterns and anomalies
  • Help document business definitions, metrics and reporting logic
  • Support enhancements to existing dashboards and reports
  • Assist with testing and validation of reports to ensure data accuracy and consistency
  • Help maintain data quality and reporting standards
  • Work with cross functional teams to understand business requirements
  • Support ad-hoc reporting and analysis requests
  • Assist in preparing presentation materials and summaries for process stakeholders
  • Help document process workflows
  • Support continuous improvement initiatives related to analytics and reporting efficiency
  • Assist in defining and validating key performance indicators
  • Perform QA checks to validate data accuracy
Desired Qualifications
  • Completion of Junior year in Science or Engineering or a related field, preferred
  • Intern experience in related environment, preferred

About the company

Tandem Diabetes Care designs and sells insulin pumps and related software for people with diabetes. Its flagship product is the t:slim X2 insulin pump, a subcutaneous device that delivers insulin and can work with other diabetes management devices through interoperable technology. A key feature is Basal-IQ, which uses continuous glucose monitoring data to predict low blood sugar and pause insulin delivery to prevent hypoglycemia. The company generates revenue from selling pumps and accessories like infusion sets and cartridges, as well as software updates and subscriptions for advanced management features, creating recurring income. Tandem differentiates itself with interoperable hardware and software that aim to simplify diabetes care and integrate with other devices, not just sell a single pump. Its goal is to improve diabetes management and quality of life by providing user-friendly, connected insulin delivery and management solutions for patients aged six and older.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2006

Get referred to Tandem Diabetes Care

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales reached $254.6 million, up 6%, with 57% gross margin.
  • August 6, 2026 guidance reaffirmed $1.065 billion-$1.085 billion sales and 5%-6% EBITDA.
  • Android compatibility and 510(k) submission for Mobi tubeless broaden the installed base.

What critics are saying

  • Commercial chief Mark Novara exited May 18, 2026, weakening execution during channel transition.
  • Q2 2026 sales still trail guidance; U.S. pump demand depends on pharmacy adoption.
  • Roche settlement legacy and diabetes-device liability expose Tandem to costly recalls and litigation.

What makes Tandem Diabetes Care unique

  • Tandem Mobi adds tubeless capability to the same 2026 hardware platform.
  • Control-IQ+ won FDA pregnancy clearance on April 27, 2026, first in U.S.
  • Pay-as-you-go pharmacy reimbursement lowers upfront costs while locking in recurring supply revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Holidays

401(k) Company Match

Remote Work Options

Hybrid Work Options

Employee Stock Purchase Plan

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 1%
The Diabetes Times
Sep 10th, 2026
Abbott's Libre established as the "most connected CGM in the world"

Abbott's Libre established as the "most connected CGM in the world" 10th September 2026 Abbott today announced the integration of its FreeStyle Libre 3 Plus sensor with Insulet's Omnipod(R) 5 Automated Insulin Delivery (AID) System in the UK, further expanding connected care options for people living with Type 1 diabetes who use a Libre sensor. The full UK availability of this latest integration builds on Abbott's FreeStyle Libre 3 Plus sensor and Tandem Diabetes Care's t:slim X2 insulin pump integration, which became available this summer. Based on the number of pump users having the ability to connect with Libre technology globally these latest partnerships establish Libre as the most connected continuous glucose monitoring (CGM) technology in the world*, providing users with access to more pump options globally than any other CGM. Today, in the UK, Abbott's connected diabetes management solutions are compatible with the following automated insulin delivery systems, or insulin pumps: * Insulet's Omnipod(R) 5 with both the FreeStyle Libre 3 Plus and the FreeStyle Libre 2 Plus sensors * Tandem Diabetes Care's t:slim X2 insulin pump with the FreeStyle Libre 3 Plus sensor * mylife Diabetes Care's YpsoPump insulin pump with the FreeStyle Libre 3 Plus sensor * MiniMed(TM) 780G system with the Instinct sensor, made exclusively by Abbott and distributed by Medtronic Hybrid closed loop systems like these combine a CGM with an insulin pump to automatically adjust insulin delivery based on glucose readings. They help people spend less time managing their condition and more time focusing on the things that matter to them. Libre technology provides real-time, personalised insights to help people understand how food, activity and medications affect their bodies. The latest Libre innovation is the world's first dual glucose-ketone sensor, which monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis, a serious diabetes-related complication. Graeme Scott, 58, from Angus, who lives with type 1 diabetes said: "My life has changed immensely for the better since starting on a hybrid closed loop system. Having my sensor and pump working together gives me greater confidence and flexibility day-to-day, helping reduce the burden of managing diabetes. The technology means I spend less time thinking about my glucose levels and more time focusing on the things I enjoy. I'm running my own life instead of letting diabetes run it for me." Julia Hammac, General Manager for Abbott's diabetes care business in the UK, said: "For people living with type 1 diabetes, having access to technologies that work seamlessly together can make a meaningful difference to day-to-day diabetes management. By expanding our hybrid closed loop partnerships, we're giving people more choice in how they manage their condition and helping make advanced diabetes technologies more accessible through connected care solutions." Hilary Nathan, Director of Policy and Communications at Breakthrough T1D said: "For many people living with type 1 diabetes, technology is part of everyday life. Having choice really matters. Everyone's experience of diabetes is different, and what works brilliantly for one person may not be right for another. We welcome developments that give people more options and greater flexibility in how they manage their condition, allowing them to choose technology that fits their individual needs, preferences and lives. Ultimately, we want to see a technology landscape shaped around the people who use it, with the freedom to choose the tools that work best for them and today's announcement helps us take one step further towards that." *Data on File, Abbott Diabetes Care

Yahoo Finance
Sep 9th, 2026
Tandem Diabetes rises 59% as Mobi tubeless pump awaits FDA clearance

Tandem Diabetes Care is positioned for growth through expanding product choices and a pay-as-you-go reimbursement model that lowers upfront costs whilst supporting higher recurring supply revenue. The company submitted a 510(k) for its Mobi tubeless pump targeting a 2026 launch and received FDA approval to begin a pivotal study for its fully closed-loop AIDANET programme. In the second quarter of 2026, pharmacy sales reached 10% of US sales, up from 6% in the first quarter, with formulary coverage at approximately 45%. Tandem reaffirmed its 2026 sales guidance of $1.065-$1.085 billion. The stock has risen 59% over the past year, against a 5.4% industry decline. The company holds a Zacks Rank #3 (Hold) with a market capitalisation of $1.05 billion.

Yahoo Finance
Aug 15th, 2026
Tandem Diabetes meets Q2 expectations but shares fall on US pump shipment concerns

Tandem Diabetes met Wall Street's revenue and profit expectations in Q2, reporting revenue of $254.6 million versus analyst estimates of $253.8 million. However, the market responded negatively, likely reflecting investor caution around US pump shipment pace and the company's business model transition. Management highlighted stronger pump shipment growth internationally and early traction from its new pharmacy channel in the US. CEO John Sheridan emphasised operational efficiencies and expanded access to technology contributed to improved margins. The company reconfirmed its full-year revenue guidance of $1.08 billion at the midpoint. Operating margin improved to -5.4%, up from -21.5% in the same quarter last year. Analyst questions focused on pharmacy transition progress, type 2 diabetes retention trends, and the timeline for Mobi tubeless FDA clearance and launch.

Yahoo Finance
Aug 6th, 2026
Tandem Diabetes Q2 revenue hits $254.6M, meets expectations with 5.8% growth

Tandem Diabetes Care met Wall Street's revenue expectations in Q2 2026, reporting sales of $254.6 million, up 5.8% year on year. The diabetes technology company's GAAP loss of $0.31 per share aligned with analyst estimates. The company reaffirmed its full-year revenue guidance of $1.08 billion at the midpoint, close to analyst forecasts. Adjusted EBITDA of $6.42 million beat expectations by 82.2%, with a 2.5% margin. Operating margin improved to -5.4%, up from -21.5% in the same quarter last year. However, free cash flow was -$38.67 million, compared to -$15.7 million in Q2 2025. Analysts expect revenue to grow 9.3% over the next 12 months. Over the past five years, Tandem Diabetes has grown sales at an 11.5% compounded annual growth rate.

MarketBeat
Jul 30th, 2026
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) given consensus rating of "Hold" by analysts.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) given consensus rating of "Hold" by analysts. July 30, 2026 Key points. * Analysts rate Tandem Diabetes Care "Hold" overall: Of 22 firms, 11 recommend holding, nine recommend buying, one strongly recommends buying, and one recommends selling. The average 12-month price target is $28.73. * Recent analyst actions were mixed, with TD Cowen raising its target to $28 while Bank of America and Citigroup cut targets to $25 and $17, respectively. * Tandem reported better-than-expected quarterly results, including an adjusted loss of $0.30 per share versus the $0.46 expected and revenue of $247.2 million, up 5.5% year over year. Shares opened at $18.59, while several institutional investors recently established or expanded positions. * Interested in Tandem Diabetes Care? Here are five stocks we like better. Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twenty-two research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $28.7250. TNDM has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Tandem Diabetes Care in a research note on Tuesday, June 23rd. They issued a "hold" rating and a $15.50 target price for the company. TD Cowen restated a "buy" rating and set a $28.00 price target (up from $25.00) on shares of Tandem Diabetes Care in a research note on Monday, April 20th. Bank of America decreased their price target on shares of Tandem Diabetes Care from $35.00 to $25.00 and set a "neutral" rating for the company in a report on Monday, May 18th. Benchmark assumed coverage on shares of Tandem Diabetes Care in a research note on Monday, May 11th. They set a "hold" rating for the company. Finally, Citigroup reissued a "neutral" rating and set a $17.00 price objective (down from $22.00) on shares of Tandem Diabetes Care in a report on Thursday, May 28th. Institutional trading of Tandem Diabetes Care. A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Freestone Grove Partners LP acquired a new position in shares of Tandem Diabetes Care in the third quarter valued at about $22,706,000. First Light Asset Management LLC purchased a new position in shares of Tandem Diabetes Care in the fourth quarter worth about $23,947,000. BNP Paribas Financial Markets lifted its holdings in shares of Tandem Diabetes Care by 468.5% during the fourth quarter. BNP Paribas Financial Markets now owns 1,248,481 shares of the medical device company's stock worth $27,442,000 after purchasing an additional 1,028,866 shares during the period. Marshall Wace LLP acquired a new stake in shares of Tandem Diabetes Care during the fourth quarter worth about $19,244,000. Finally, Defilade Capital Management L.P. purchased a new stake in Tandem Diabetes Care in the first quarter valued at approximately $14,606,000. Tandem Diabetes Care trading up 4.7%. Tandem Diabetes Care stock opened at $18.59 on Thursday. The stock has a 50-day moving average of $16.36 and a two-hundred day moving average of $18.92. The company has a debt-to-equity ratio of 4.54, a quick ratio of 3.07 and a current ratio of 3.58. Tandem Diabetes Care has a one year low of $9.98 and a one year high of $29.65. The stock has a market cap of $1.27 billion, a PE ratio of -13.28 and a beta of 1.58. Discover more Cryptocurrency News investment Stock Screener Tool Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The medical device company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.16. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The business had revenue of $247.22 million for the quarter, compared to analyst estimates of $240.41 million. During the same quarter in the previous year, the firm earned ($0.66) earnings per share. The company's revenue was up 5.5% on a year-over-year basis. On average, research analysts anticipate that Tandem Diabetes Care will post -0.72 EPS for the current fiscal year. About Tandem Diabetes Care. Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim(R) Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities. The company's flagship offering, the t:slim X2(R) Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Tandem Diabetes Care, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list. While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

INACTIVE